Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R E Chatelain

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
The Journal of Pathology|January 1, 1983
Differing patterns of altered glucocorticoid secretion in experimental malignant and benign hypertension. Influences upon the lymphoid system and on arterial connective tissue metabolismR E Chatelain, F M Bumpus, C L Chernicky, et al.
The American Journal of Physiology|June 1, 1980
Development of two-kidney Goldblatt hypertension in rats under dietary sodium restrictionH Muñoz-Ramírez, R E Chatelain, F M Bumpus, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1990
Antihypertensive effects of CGS 19281A, an inhibitor of phenylethanolamine-N-methyltransferaseR E Chatelain, M J Manniello, B N Dardik, et al.
The Journal of Laboratory and Clinical Medicine|May 1, 1981
Impaired arterial collagen and elastin metabolism in experimental malignant hypertensionR E Chatelain, L A Ehrhart, P M DiBello, et al.
Journal of Cardiovascular Pharmacology|December 5, 1997
Effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, CGS 30440, on blood pressure and cardiac hypertrophy in spontaneously hypertensive ratsR L Webb, M L Abramson, M E Beil, et al.
Cleveland Clinic Journal of Medicine|June 1, 1989
Malignant hypertension, fibrinoid deposition, and fibrinogen electrophoresisB N Dardik, J R Shainoff, R E Chatelain, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 13, 1998
Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11R E Chatelain, R D Ghai, A J Trapani, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
The Journal of Pathology|January 1, 1983
Differing patterns of altered glucocorticoid secretion in experimental malignant and benign hypertension. Influences upon the lymphoid system and on arterial connective tissue metabolismR E Chatelain, F M Bumpus, C L Chernicky, et al.
The American Journal of Physiology|June 1, 1980
Development of two-kidney Goldblatt hypertension in rats under dietary sodium restrictionH Muñoz-Ramírez, R E Chatelain, F M Bumpus, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1990
Antihypertensive effects of CGS 19281A, an inhibitor of phenylethanolamine-N-methyltransferaseR E Chatelain, M J Manniello, B N Dardik, et al.
The Journal of Laboratory and Clinical Medicine|May 1, 1981
Impaired arterial collagen and elastin metabolism in experimental malignant hypertensionR E Chatelain, L A Ehrhart, P M DiBello, et al.
Journal of Cardiovascular Pharmacology|December 5, 1997
Effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, CGS 30440, on blood pressure and cardiac hypertrophy in spontaneously hypertensive ratsR L Webb, M L Abramson, M E Beil, et al.
Cleveland Clinic Journal of Medicine|June 1, 1989
Malignant hypertension, fibrinoid deposition, and fibrinogen electrophoresisB N Dardik, J R Shainoff, R E Chatelain, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 13, 1998
Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11R E Chatelain, R D Ghai, A J Trapani, et al.
Pageof 2